Alicja Przybylska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicja Przybylska has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Katarzyna Dopierała
Institute of Chemical Technology and Engineering, Poznan University of Technology, Berdychowo 4, 60-965 Poznań, Poland
2 shared publications - Agnieszka Kołodziejczak-Radzimska
Institute of Chemical Technology and Engineering, Faculty of Chemical Technology, Poznan University of Technology, Berdychowo 4, PL-60965 Poznan, Poland
1 shared publication Bozena Michniak-Kohn
Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey, 160 Frelinghuysen Road, Piscataway 08854, NJ, United States; Center for Dermal Research, Rutgers, The State University of New Jersey, 145 Bevier Road, Piscataway 08854, NJ, United States
1 shared publication- Cristina Satriano
Nano Hybrid Biointerfaces Laboratory (NHBIL), Department of Chemical Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy
1 shared publication - Francesco Attanasio
Institute of Crystallography National Research Council , Via Paolo Gaifami 18
1 shared publication - Irina Naletova
Institute of Crystallography, CNR, P. Gaifami 18, Catania 95126, Italy
1 shared publication
Latest Publications
- 22 May 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 225, 115122
Tuning lipid monolayer behavior with soluble surfactants: A pathway to enhanced ultradeformable drug carriers
- 22 May 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 225, 115122
Tuning lipid monolayer behavior with soluble surfactants: A pathway to enhanced ultradeformable drug carriers
- Open Access
- 4 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3273
Alverine-Loaded Lipid Bilayer–Graphene Oxide Hybrids as a Novel Nanomedicine Platform for Neural Cancer
Graphene oxide (GO)–lipid hybrid nanostructures represent a promising class of multifunctional platforms for drug delivery and fluorescence-guided cellular imaging. In this study, we developed a graphene oxide-supported lipid bilayer system composed of rhodamine-labeled phosphatidylcholine (POPC-Rhod) for the delivery of the repurposed antispasmodic drug alverine citrate (ALV) to neuroblastoma cells. The hybrid nanostructures were assembled using two drug-loading strategies and characterized by UV–Vis spectroscopy, fluorescence analysis, dynamic light scattering, and atomic force microscopy to evaluate molecular interactions, vesicle size distribution, and nanomechanical properties. In vitro studies were performed using human neuroblastoma SH-SY5Y cells and their retinoic acid-differentiated neuronal-like counterparts. Confocal microscopy confirmed efficient cellular uptake of the fluorescent lipid–graphene hybrids, while viability and mitochondrial reactive oxygen species assays revealed differentiation-dependent cellular responses. ALV-loaded hybrids induced cytotoxic effects in proliferating neuroblastoma cells, whereas differentiated neuron-like cells exhibited greater tolerance and, at moderate concentrations, preserved viability despite increased oxidative stress. These findings demonstrate that graphene oxide–lipid hybrids can act as fluorescence-traceable drug delivery platforms and highlight the potential of alverine as a candidate for repurposing in neural cancer models. The system presented here provides a proof-of-concept framework for the development of multifunctional nanocarriers integrating therapeutic delivery with imaging capabilities.
- 4 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3273
Open AccessAlverine-Loaded Lipid Bilayer–Graphene Oxide Hybrids as a Novel Nanomedicine Platform for Neural Cancer
Graphene oxide (GO)–lipid hybrid nanostructures represent a promising class of multifunctional platforms for drug delivery and fluorescence-guided cellular imaging. In this study, we developed a graphene oxide-supported lipid bilayer system composed of rhodamine-labeled phosphatidylcholine (POPC-Rhod) for the delivery of the repurposed antispasmodic drug alverine citrate (ALV) to neuroblastoma cells. The hybrid nanostructures were assembled using two drug-loading strategies and characterized by UV–Vis spectroscopy, fluorescence analysis, dynamic light scattering, and atomic force microscopy to evaluate molecular interactions, vesicle size distribution, and nanomechanical properties. In vitro studies were performed using human neuroblastoma SH-SY5Y cells and their retinoic acid-differentiated neuronal-like counterparts. Confocal microscopy confirmed efficient cellular uptake of the fluorescent lipid–graphene hybrids, while viability and mitochondrial reactive oxygen species assays revealed differentiation-dependent cellular responses. ALV-loaded hybrids induced cytotoxic effects in proliferating neuroblastoma cells, whereas differentiated neuron-like cells exhibited greater tolerance and, at moderate concentrations, preserved viability despite increased oxidative stress. These findings demonstrate that graphene oxide–lipid hybrids can act as fluorescence-traceable drug delivery platforms and highlight the potential of alverine as a candidate for repurposing in neural cancer models. The system presented here provides a proof-of-concept framework for the development of multifunctional nanocarriers integrating therapeutic delivery with imaging capabilities.